HsCRP in the Prognosis of Patients After PCI：a Multi-center Study

Study Overview
=================
Brief Summary
-----------------
Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the prognosis of these patients followed up for 1 years at 14 hospitals in China.

Official Title
-----------------
High-sensitivity C-reactive Protein (hsCRP) in the Prognosis of Patients After Coronary Intervention (PCI) : a Multi-center Prospective Study

Conditions
-----------------
hsCRP

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who understand and sign the informed consent voluntarily; Age ≥ 18 years old and ≤ 80 years old, regardless of sex; The hospitalized patients with coronary heart disease undergoing PCI; Complete all planned PCI during hospitalization. Exclusion Criteria: Acute, chronic or recurrent infectious diseases; Immune diseases or immune-related diseases; Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs; Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures; The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACCE | A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, ischemia-driven revascularization | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause death | Occurrence of all-cause death | 12 months | 
| cardiovascular death | Occurrence of cardiovascular death | 12 months | 
| nonfatal myocardial infarction | Occurrence of nonfatal myocardial infarction | 12 months | 
| nonfatal stroke | Occurrence of of nonfatal stroke | 12 months | 
| ischemia-driven revascularization | Occurrence of ischemia-driven revascularization | 12 months | 
| hospitalization for unstable angina | Occurrence of hospitalization for unstable angina | 12 months | 
| stent/scaffold thrombosis | Occurrence of stent/scaffold thrombosis | 12 months | 
| in-stent restenosis | Occurrence of in-stent restenosis | 12 months | 
| bleeding | Occurrence of bleeding | 12 months |